ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

3:00PM-4:30PM: Abstract Number: 2230

Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

3:00PM-4:30PM: Abstract Number: 2229

Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

3:00PM-4:30PM: Abstract Number: 2206

Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:30PM: Abstract Number: 2197

Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US

Abstracts: Health Services Research

4:30PM-5:30PM: Abstract Number: 2236

Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology

Abstracts: Fibromyalgia and Other Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 2241

Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 2240

Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-5:30PM: Abstract Number: 2235

Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial

Abstracts: Fibromyalgia and Other Clinical Pain Syndromes

4:30PM-6:00PM: Abstract Number: 2259

Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-6:00PM: Abstract Number: 2254

Detection of Active Inflammatory and Structural Changes Indicative of Axial Spondyloarthritis on MRI of Sacroiliac Joint Using a Deep Learning Framework

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-6:00PM: Abstract Number: 2255

Do Fatty Lesions Explain the Association Between Inflammation and New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis?

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes II: Imaging

4:30PM-6:00PM: Abstract Number: 2239

Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial

Abstracts: Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 2245

Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials

Abstracts: Patient Outcomes, Preferences, and Attitudes: Patient Priorities and Preferences: Interventions and Transformation

4:30PM-6:00PM: Abstract Number: 2250

Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD

4:30PM-6:00PM: Abstract Number: 2252

Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes III: RA ILD

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].